Fundamentals of Biologicals Regulation: Vaccines and Biotechnology Medicines, Second Edition serves as an introduction to the international regulatory arena in which biologicals are developed, offering an overview of processes and insights into the scientific concepts underpinning global regulations. The book provides in-depth coverage of Quality by Design, Combination Products, Quality Target Product Profiles, Risk Management Plans, REMS, and switching from reliance on in vivo to in vitro analytical methods. It reflects new developments and processes accelerated by the COVID-19 vaccine…mehr
Fundamentals of Biologicals Regulation: Vaccines and Biotechnology Medicines, Second Edition serves as an introduction to the international regulatory arena in which biologicals are developed, offering an overview of processes and insights into the scientific concepts underpinning global regulations. The book provides in-depth coverage of Quality by Design, Combination Products, Quality Target Product Profiles, Risk Management Plans, REMS, and switching from reliance on in vivo to in vitro analytical methods. It reflects new developments and processes accelerated by the COVID-19 vaccine experience, including emergency use authorizations and conditional marking authorizations. New pedagogic elements and case studies have been added to improve learning outcomes. This book provides multiple levels of readership, with guidance on basic concepts, a detailed look at regulatory challenges, and practical insights into how regulators consider regulatory science and regulatory process issues across various regions, with an emphasis on the European Medicines Agency and the U.S. Food and Drug Administration.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Dr. Rebecca Sheets is currently the Vice President for the International Alliance of Biologicals Standardization, North American affiliate. She is the former Vaccine Scientific and Regulatory Specialist at the National Institute of Allergy and Infectious Diseases. Dr. Sheets served 9 years as a Scientific Reviewer in the Viral Vaccines branch of the Division of Vaccines and Related Products Applications at the Center for Biologics Evaluation and Research at the FDA. From 2006-2014, she served as Co-Chair of the World Health Organization's Study Group on Cell Substrates and as Chair of the Adventitious Agents Sub-committee, as well as authoring several WHO guidelines and publications over the past two decades. She also taught for a decade at the Catholic University of America. Before retirement, she was the Principal Consultant at Grimalkin Partners from 2013-2021.
Inhaltsangabe
SECTION I REGULATORY PROCESS 1. Introduction to the Regulatory Process for Biologicals 2. International Regulatory Convergence 3. Quality by Design (QbD) Approach to Discovery and Development 4. Communications and Formal Meetings With Regulators: Focusing on the Process Before Clinical Trial 5. Clinical Trial Authorization and investigational New Drug Applications 6. Marketing Authorization 7. Alternative Regulatory Pathways and Special Programs 8. Variations or Changes to an Approved Application 9. Good "X" Practices 10. Audits and Regulatory Compliance inspections SECTION II REGULATORY SCIENCE PART I PRECLINICAL 11. Preclinical Safety and Toxicology 12. Preclinical Pharmacology , Proof-of-Principle 13. Institutional Biosafety Committees and Regulation of Genetically Modified Organisms 14. Risk Assessments PART II PRODUCT 15. Product Construction, Manufacture, and Process Validation 16. Analytical Method Development and Validation Leading to Control Strategy and Lot Release PART Ill CLINICAL 17. Regulatory Aspects of Clinical Trials 18. Pharmacovigilance and RiskMAPs 19. Clinical Trial Ethics, Human Subjects Protections, and the Informed Consent process 20. Independent Ethics Committees and Institutional Review Boards SECTION Ill PRODUCT-SPECIFIC REGULATORY PROCESSES 21. Biosimilars 22. In Vitro Diagnostics and Biotech Medical Devices 23. Combination Products 24. Regulatory Policy and Public Health Policy
SECTION I REGULATORY PROCESS 1. Introduction to the Regulatory Process for Biologicals 2. International Regulatory Convergence 3. Quality by Design (QbD) Approach to Discovery and Development 4. Communications and Formal Meetings With Regulators: Focusing on the Process Before Clinical Trial 5. Clinical Trial Authorization and investigational New Drug Applications 6. Marketing Authorization 7. Alternative Regulatory Pathways and Special Programs 8. Variations or Changes to an Approved Application 9. Good "X" Practices 10. Audits and Regulatory Compliance inspections SECTION II REGULATORY SCIENCE PART I PRECLINICAL 11. Preclinical Safety and Toxicology 12. Preclinical Pharmacology , Proof-of-Principle 13. Institutional Biosafety Committees and Regulation of Genetically Modified Organisms 14. Risk Assessments PART II PRODUCT 15. Product Construction, Manufacture, and Process Validation 16. Analytical Method Development and Validation Leading to Control Strategy and Lot Release PART Ill CLINICAL 17. Regulatory Aspects of Clinical Trials 18. Pharmacovigilance and RiskMAPs 19. Clinical Trial Ethics, Human Subjects Protections, and the Informed Consent process 20. Independent Ethics Committees and Institutional Review Boards SECTION Ill PRODUCT-SPECIFIC REGULATORY PROCESSES 21. Biosimilars 22. In Vitro Diagnostics and Biotech Medical Devices 23. Combination Products 24. Regulatory Policy and Public Health Policy
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826